CLDN4 as a Novel Diagnostic and Prognostic Biomarker and Its Association with Immune Infiltrates in Ovarian Cancer

Figure 4

The survival analysis of CLDN4 expression in different subgroup of OC patients. (a) Age, (b) lymphatic invasion, (c) FIGO stage, and (d) histologic grade.

(a)

(b)

(c)

(d)